MaxCyte Form 4: 29,210 RSUs, 50,790 Options Granted to Director
Rhea-AI Filing Summary
MaxCyte, Inc. (MXCT) filed a Form 4 detailing the annual equity grant to non-employee director Dr. Yasir B. Al-Wakeel. On 18 June 2025 he received 29,210 restricted stock units (RSUs), each representing one share of common stock, at a cost basis of $0. The RSUs will vest in full on 18 June 2026, provided he remains in service on that date. Following the award, Dr. Al-Wakeel’s direct beneficial ownership of common stock stands at 50,577 shares.
In addition, he was granted a stock option covering 50,790 shares of common stock at an exercise price of $2.11 per share. The option was issued on 18 June 2025 and expires on 17 June 2035. All derivative securities are held directly.
The filing is purely an insider ownership update; it discloses no sales, no cash transactions, and no changes to company fundamentals. The equity awards were made under the company’s standard policy for non-employee directors and are accompanied by a power of attorney (Exhibit 24) authorising an attorney-in-fact to sign on the director’s behalf.
Positive
- Director received equity, not cash, strengthening alignment with shareholders.
Negative
- Potential dilution of ~80k shares when RSUs vest and options are exercised, though likely immaterial.
Insights
TL;DR: Routine director equity grant; aligns incentives, minimal dilution, neutral impact.
The Form 4 shows customary annual compensation: 29,210 RSUs vesting after one year and 50,790 options at $2.11, with a 10-year term. Such grants are standard for U.S.-listed biotech boards and signal that the director’s interests remain tied to shareholder value. Dilution from 80 k shares is immaterial relative to MXCT’s outstanding share count (not disclosed here but >100 m as of prior filings). No shares were sold, so market supply is unaffected. There are no red flags in vesting schedule, pricing, or volume. Overall governance posture appears conventional, producing a neutral valuation effect.
TL;DR: Insider accepts equity instead of cash; slightly positive alignment but not financially material.
While the 29 k RSUs automatically add to float upon vesting, the option strike of $2.11 sits near historical trading ranges, offering upside leverage but only if operational execution improves. The absence of sales suggests confidence, yet this is common practice for directors. From a portfolio perspective, the data neither changes earnings outlook nor risk profile; therefore, I classify the filing as neutral with a tiny positive tilt on alignment.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 50,790 | $0.00 | -- |
| Grant/Award | Common Stock | 29,210 | $0.00 | -- |
Footnotes (1)
- These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. This annual grant was made pursuant to the Issuer's Equity Grant Policy for non-employee directors. The shares underlying this grant vest on June 18, 2026, subject to the reporting person's continuous service as of such vesting date.
